MX2013008868A - Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa. - Google Patents

Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa.

Info

Publication number
MX2013008868A
MX2013008868A MX2013008868A MX2013008868A MX2013008868A MX 2013008868 A MX2013008868 A MX 2013008868A MX 2013008868 A MX2013008868 A MX 2013008868A MX 2013008868 A MX2013008868 A MX 2013008868A MX 2013008868 A MX2013008868 A MX 2013008868A
Authority
MX
Mexico
Prior art keywords
azaindolylphenyl
sulfonamides
serine
new
kinase inhibitors
Prior art date
Application number
MX2013008868A
Other languages
English (en)
Spanish (es)
Inventor
Heinz Stadtmueller
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2013008868A publication Critical patent/MX2013008868A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013008868A 2011-02-02 2012-02-02 Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa. MX2013008868A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11153087 2011-02-02
EP11181258 2011-09-14
PCT/EP2012/051796 WO2012104388A1 (en) 2011-02-02 2012-02-02 New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2013008868A true MX2013008868A (es) 2013-08-14

Family

ID=45558742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008868A MX2013008868A (es) 2011-02-02 2012-02-02 Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa.

Country Status (15)

Country Link
US (1) US8889684B2 (https=)
EP (1) EP2670749B1 (https=)
JP (1) JP5850952B2 (https=)
KR (1) KR20140014149A (https=)
CN (1) CN103476773A (https=)
AU (1) AU2012213390A1 (https=)
BR (1) BR112013019714A2 (https=)
CA (1) CA2825279A1 (https=)
CL (1) CL2013002063A1 (https=)
EA (1) EA201300874A1 (https=)
IL (1) IL227399A0 (https=)
MX (1) MX2013008868A (https=)
PH (1) PH12013501618A1 (https=)
UY (1) UY33890A (https=)
WO (1) WO2012104388A1 (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
EP2398797B1 (en) 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
CN105037355B (zh) 2009-08-10 2017-06-06 萨穆梅德有限公司 Wnt信号传导途径的吲唑抑制剂及其治疗用途
LT3001903T (lt) 2009-12-21 2018-01-10 Samumed, Llc 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
IN2014CN02646A (https=) 2011-09-14 2015-08-07 Samumed Llc
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
NZ629282A (en) 2012-05-04 2017-04-28 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
AU2013266438B2 (en) 2012-05-22 2017-09-07 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
EP2943198B1 (en) 2013-01-08 2019-07-17 Samumed, LLC 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
US11021752B2 (en) 2013-03-15 2021-06-01 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
US9555031B2 (en) * 2014-04-11 2017-01-31 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
EP3164508B1 (en) 2014-07-02 2023-06-07 Myriad myPath, LLC Genes and gene signatures for diagnosis and treatment of melanoma
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
CN107454899B (zh) * 2014-10-27 2020-05-29 大学健康网络 Ripk2抑制剂及用其治疗癌症的方法
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
US10562902B2 (en) 2015-08-13 2020-02-18 Beijing Hanmi Pharmaceutical Co., Ltd. IRAK4 inhibitor and use thereof
MX380092B (es) 2015-11-06 2025-03-11 Samumed Llc Tratamiento de la osteoartritis.
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
MX390577B (es) 2016-06-01 2025-03-20 Samumed Llc Proceso de preparación de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida.
JP2019535672A (ja) 2016-10-21 2019-12-12 サミュメッド リミテッド ライアビリティ カンパニー インダゾール−3−カルボキサミドの使用方法およびwnt/β−カテニンシグナル伝達経路阻害剤としてのそれらの使用
MA46696A (fr) 2016-11-07 2019-09-11 Samumed Llc Formulations injectables à dose unique prêtes à l'emploi
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
KR20250117470A (ko) * 2016-12-23 2025-08-04 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
SG11202003635TA (en) * 2017-10-26 2020-05-28 Xynomic Pharmaceuticals Inc Crystalline salts of a b-raf kinase inhibitor
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2022056368A1 (en) 2020-09-14 2022-03-17 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of estrogen receptor
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特(成都)生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253930T3 (es) * 1998-09-18 2006-06-01 ABBOTT GMBH & CO. KG 4-aminopirrolopirimidinas como inhibidores de quinasa.
JP2003509428A (ja) * 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療薬としてのピラゾロピリミジン
ATE329909T1 (de) 2002-11-27 2006-07-15 Boehringer Ingelheim Pharma 1,2,3-triazolamid-derivate als cytokininhibitoren
JP4769720B2 (ja) * 2003-08-21 2011-09-07 オーエスアイ・ファーマシューテイカルズ・エル・エル・シー N−置換ベンズイミダゾリルc−Kit阻害剤
ATE501128T1 (de) 2003-12-03 2011-03-15 Boehringer Ingelheim Pharma 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion
DK1704145T3 (da) * 2004-01-12 2012-09-24 Ym Biosciences Australia Pty Selektive kinaseinhibitorer
PT1725544E (pt) 2004-03-09 2009-07-02 Boehringer Ingelheim Pharma 3-[4-heterociclil-1,2,3-triazol-1-il]-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crónicas
US7485657B2 (en) 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
US20060004197A1 (en) * 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
US7531560B2 (en) 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
JP2007076376A (ja) 2005-09-09 2007-03-29 Yanmar Co Ltd トラクタ
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US7858804B2 (en) 2006-04-18 2010-12-28 Boehringer Ingelheim International Gmbh Process for making cytokine inhibiting compounds containing 4- and 5-imidazolyl rings and the intermediates thereof
CN101501023A (zh) 2006-07-07 2009-08-05 贝林格尔.英格海姆国际有限公司 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途
CA2692379A1 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2215094B1 (en) * 2007-11-15 2016-01-27 YM BioSciences Australia Pty Ltd N-containing heterocyclic compounds
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN102712646A (zh) * 2009-08-28 2012-10-03 阵列生物制药公司 Raf抑制剂化合物及其使用方法
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
US8546443B2 (en) 2010-12-21 2013-10-01 Boehringer Ingelheim International Gmbh Benzylic oxindole pyrimidines
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
WO2012104388A1 (en) 2012-08-09
EP2670749A1 (en) 2013-12-11
EA201300874A1 (ru) 2014-02-28
US20130029993A1 (en) 2013-01-31
BR112013019714A2 (pt) 2016-10-18
JP2014504622A (ja) 2014-02-24
PH12013501618A1 (en) 2013-09-30
KR20140014149A (ko) 2014-02-05
CN103476773A (zh) 2013-12-25
CA2825279A1 (en) 2012-08-09
JP5850952B2 (ja) 2016-02-03
UY33890A (es) 2012-08-31
CL2013002063A1 (es) 2013-12-27
EP2670749B1 (en) 2016-01-27
US8889684B2 (en) 2014-11-18
IL227399A0 (en) 2013-09-30
AU2012213390A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
MX2013008868A (es) Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa.
CO6640285A2 (es) 5-alquinil-pirimidinas
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
ECSP13012448A (es) Nuevas aminopirazoloquinazolinas.
UY38712A (es) Lactamas fusionadas de arilo y heteroarilo
MX2012003101A (es) Derivados de pirimidina como inhibidores de la proteina tirosina quinasa 2.
MX2015015738A (es) Derivados del bipirazol como inhibidores de janus cinasa (jak).
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
MX2017002656A (es) Compuestos que inhiben la proteína mcl-1.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CR20150326A (es) Inhibidores de autotaxina
MX2017016996A (es) Nuevos derivados aminoacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
PE20151023A1 (es) Triazolopirazinas
UY35129A (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
ECSP16074478A (es) Compuestos novedosos
ECSP11011558A (es) Nuevos compuestos químicos.
NI201500096A (es) Compuesto químicos
UY32009A (es) 5-alquinil-pirimidinas
CO6290768A2 (es) Tiazolil-dihidro-indazoles
CO6460762A2 (es) 5-alquinil-piridinas
CO6592046A2 (es) 5-alquinil pirimidas y su uso como inhibidores de quinasa
ECSP11011464A (es) Tia-triaza-ciclopentazulenos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal